

Neurodegenerative Diseases Treatment Patent: White Paper

Type: Review Article

Received: June 22, 2026

Published: September 02, 2026

Christina Rahm*

DRC VENTURES LLC, USA

***Corresponding Author:** Christina Rahm, DRC VENTURES LLC, USA.

Citation:

Christina Rahm. "Neurodegenerative Diseases Treatment Patent: White Paper". PriMera Scientific Surgical Research and Practice 8.3 (2026): 13-16.

Copyright:

© 2026 Christina Rahm. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Neurodegenerative diseases (Alzheimer development, Parkinson, and Huntington's) are one of the emerging health challenges in the world which is characterized by the gradual destruction of brain cells and resultant cognitive and motor disability. The pathophysiology of these diseases is complicated and multifactorial and comprises a set of genetic, environmental, and biological determinants. Nevertheless, shared pathological pathways that support these disorders include oxidative stress, neuroinflammation, mitochondrial dysfunction and deposition of toxic proteins. Given the significance of these debilitating conditions, in the recent past, there have been scientific patents on new therapeutic formulations, which promise new avenues of fighting or relieving symptoms of the disease. This white paper discusses the potential contribution of a particular scientific patent, that consists of proprietary formulations to these mechanisms, to the treatment of neurodegenerative disease progress. The article identifies the causes of these diseases as oxidative stress, inflammation, mitochondrial pathology, and environmental toxins and how these patented formulations have the potential to provide therapeutic advantages.

Neurodegeneration and Oxidative Stress

Oxidative stress is one of the most important aspects in the development of neurodegenerative diseases and it happens when the amount of reactive oxygen species (ROS) produced surpasses the antioxidant capabilities of the body. ROS may induce cellular damage through oxidation of lipids, proteins, and DNA, induce mitochondrial dysfunction, neuronal death, and additional spread of oxidative damage (Altahrawi et al., 2025; Tang et al., 2025). This process increases the rate of neuronal degeneration in the brain especially in the areas of the brain that are involved in memory and motor abilities in Alzheimer and Parkinson disease. The discussed scientific patent presents a treatment with natural antioxidant compounds, including curcumin, which have been demonstrated to neutralize the effects of ROS and minimize oxidative brain damage (Islam et al., 2025). Curcumin is a derivative of turmeric and has a strong antioxidant effect, and research has shown that it can reduce oxidative stress by scavenging free radicals and increasing endogenous activities of antioxidant enzymes (Jiao et al., 2025; Wang et al., 2025). The proposed treatment including curcumin to the formulation would be helpful to delay the development of neurodegenerative diseases, as it would alleviate oxidative stress in neurons.

Neurodegeneration and Inflammation

Another important issue in the pathogenesis and course of neurodegenerative diseases is neuroinflammation. The sustained activation of the microglial cells, the immune cells of the brain lead to the release of pro-inflammatory cytokines and ROS to provide a toxic environment that increases

neuronal degeneration (Folta et al., 2025). Amyloid plaques accumulation in the case of Alzheimer and alpha-synuclein misfolding and aggregation in the case of Parkinson's disease also contribute to the development of neuroinflammation in both cases. The formulations of the patent incorporate such compounds as zinc and vitamin D which are known to regulate immune responses and have anti-inflammatory properties. Zinc is an essential trace mineral involved in numerous physiological processes throughout the body. Research suggests it can help inhibit microglial activation, thereby reducing neuroinflammatory responses in the brain (Huang et al., 2025). On the same note, vitamin D is an essential element involved in the regulation of the immune system, and not a single study has shown that vitamin D is related to a lower level of neuroinflammation (Bailo et al., 2022). The formulations that are contained in the patent may reduce the adverse effects of neuroinflammation by incorporating these compounds, which may slow the onset of neurodegenerative diseases.

Mitochondrial Dysregulation and Neurodegeneration

The area of the cell that is critical to the health of the neurons is mitochondria, which are the energy producing organelles of the cell. In neurodegenerative diseases, the dysfunction of mitochondria results in the inability of energy to produce, excessive production of ROS, and cell death (Yang, 2025). In such diseases as Alzheimer and Parkinson, failure of mitochondria leads to the loss of neurons and the further course of the illness. The accumulation of lethal proteins, including amyloid-beta and alpha-synuclein, is also closely related to mitochondrial dysfunction, which has an additional negative impact on the functioning of cells and causes oxidative stress (Mason, 2025). The structures of the patent contain the polyphenols that are proven to foster the health of the mitochondria through improving mitochondrial biogenesis and mitigating the impact of oxidative injury. Polyphenols present in green tea, berries, etc. have been reported to activate cellular pathways that promote the functioning of the mitochondrion and prevent the damage caused by ROS (Chen et al., 2025). The proposed formulations may be useful in the pathogenesis of neurodegenerative diseases by correcting mitochondrial dysfunction, which results in cellular energy production, oxidative damage, and neuronal survival.

Environmental Toxins and Neurodegeneration

Heavy metals, pesticides, and air pollution are environmental toxins that have been attributed to the development and development of neurodegenerative diseases. These toxins influence neuron damage via oxidative strain, inflammation and mitochondrion dysfunction, a typical characteristic of illnesses such as Parkinson and Alzheimer (Kulcsarova et al., 2025). Examples include pesticides which have been demonstrated to cause higher risks of developing Parkinson disease by destabilizing the mitochondrial functioning and facilitation of neuroinflammation (Ribeiro et al., 2025). The patent touches on the contribution of the environmental toxins using zeolite extract, which is a natural compound that is not only detoxifying. Zeolite can adsorb the heavy metal and other toxic substances so that they do not build up in the body and lead to oxidative stress (Caproni et al., 2025). The patent will potentially provide the solution to this toxic burden on the brain by incorporating zeolite into the formulations especially for individuals who had been exposed to environmental pollutants or individuals with history of occupational exposure to neurotoxic substances.

Zinc and Magnesium in Nerve Disorder Diseases

Zinc and magnesium are critical minerals that are also involved in various major biological processes such as neurotransmission, enzyme activity, and control over oxidative stress. The shortage of these minerals has been associated with cognitive impairment and high chances of developing neurodegenerative disorders (Lee et al., 2023). Zinc has also been found to regulate synaptic plasticity as well as has been found to regulate the inflammatory response within the brain making it an essential nutrient in protecting the brain. Magnesium, however, is very important to the mitochondrial activity and the energy production in the cells that are vital in the health of the neurons (Khan et al., 2025). The formulations of the patent contain zinc and magnesium that would cover the possible deficiencies that may lead to the development of the neurodegenerative diseases. The formulations may promote the functions of the neurons, lowering the inflammation, and protecting against neurodegeneration by replacing these essential minerals. This two-sided treatment can be a more holistic treatment option, especially in the case of patients who are deficient in nutrients or those who are more susceptible to neurodegenerative conditions.

The Curcumin and Neuroplasticity

The brain is capable of self-organization in response to cognitive demands and neurodegenerative disease recovery through a process known as neuroplasticity which is the ability of the brain to reorganize and establish new neural connections. Curcumin as an antioxidant and anti-inflammatory substance has also been found to stimulate neuroplasticity by regulating epigenetic processes and stimulating the proliferation of new neurons (Jiao et al., 2025). When neurons are damaged leading to cognitive and motor impairments because of neurodegenerative diseases, the increase in neuroplasticity may be used to restore the functions that have been lost and promote the wellbeing of patients (Zhang et al., 2025). The patent will not only minimize oxidative stress and inflammation but also help the brain to become healthy and heal by adding curcumin to the treatment protocols (Castelli et al., 2025). This might prove useful especially during the initial phases of neurodegenerative diseases when neuroplasticity might be important in cognitive preservation and recovery.

Conclusion

The proposed formulations of the scientific patent are an encouraging line of treatment and management of neurodegenerative diseases. The patent presents a combined approach to preventing the disease by attacking the leading underlying pathways like oxidative stress, inflammation, mitochondrial dysfunction, and exposure to environmental toxins, which can be used to delay the progression of the disease and enhance patient outcomes. Natural substances, such as curcumin, zinc, magnesium, and zeolite, make it a new method of therapy which not only treats the symptoms but also the reasons of neurodegeneration. Although clinical trials should be conducted to establish effectiveness of these formulations, the patent presents a new challenge to the existing literature aimed at creation of more effective treatment of neurodegenerative diseases. With the continuing development of knowledge on the pathophysiology of these diseases, new drugs such as those discussed in this patent can greatly improve the quality of life of those with Alzheimer, Parkinson, and other neurodegenerative diseases.

References

1. Altahrawi AY, James AW and Shah ZA. "The Role of Oxidative Stress and Inflammation in the Pathogenesis and Treatment of Vascular Dementia". *Cells* 14.8 (2025): 609-609.
2. Bailo P, et al. "The role of oxidative stress in neurodegenerative diseases and potential antioxidant therapies". *Advances in Laboratory Medicine* 3.4 (2022): 342-350.
3. Caproni S, Fonzo AD and Colosimo C. "Oxidative Stress: A New Pathophysiological Pathway in Parkinson's Disease and a Potential Target of the Brain-Sport Crosstalk". *Parkinson's Disease* 2025.1 (2025).
4. Castelli S, Carinci E and Baldelli S. "Oxidative Stress in Neurodegenerative Disorders: A Key Driver in Impairing Skeletal Muscle Health". *International Journal of Molecular Sciences* 26.12 (2025): 5782.
5. Chen B., et al. "Mitochondrial quality control in neurodegenerative diseases: from molecular mechanisms to natural product therapies". *Frontiers in Physiology* 16 (2025): 1695681-1695681.
6. Chen G., et al. "Polyphenols and Alzheimer's Disease: A Review on Molecular and Therapeutic Insights With In Silico Support". *Food Science & Nutrition* 13.9 (2025).
7. Foltá J, Rzepka Z and Wrzeński D. "The Role of Inflammation in Neurodegenerative Diseases: Parkinson's Disease, Alzheimer's Disease, and Multiple Sclerosis". *International Journal of Molecular Sciences* 26.11 (2025): 5177.
8. Huang S-H., et al. "Association of zinc deficiency and risk of new-onset dementia: a retrospective cohort study". *Frontiers in Nutrition* 12 (2025): 1666887-1666887.
9. Islam MR., et al. "Neuroprotective Potential of Curcumin in Neurodegenerative Diseases: Clinical Insights Into Cellular and Molecular Signaling Pathways". *Journal of Biochemical and Molecular Toxicology* 39.8 (2025).
10. Jiao H., et al. "Curcumin and neuroplasticity: epigenetic mechanisms underlying cognitive enhancement in aging and neurodegenerative disorders". *Frontiers in Aging Neuroscience* 17 (2025).
11. Khan MS., et al. "Targeting ferroptosis for neuroprotection: potential therapeutic avenues in neurodegenerative and neuropsychi-

- atric diseases". *Frontiers in Physiology* 16 (2025).
12. Kulcsárová K, Piel A and Schaeffer E. "Environmental toxins in neurodegeneration - a narrative review". *Neurological Research and Practice* 7.1 (2025).
 13. Lee J, Park S and Jang W. "Serum zinc deficiency could be associated with dementia conversion in Parkinson's disease". *Frontiers in Aging Neuroscience* 15 (2023).
 14. Mason S. "Say hello to my little friend... micro nutraceuticals in neuroenergetics, neuronal health, and neurodegenerative diseases". *Frontiers in Neuroscience* 19 (2025).
 15. Ribeiro PR, et al. "Nutritional Approaches in Neurodegenerative Disorders: A Mini Scoping Review with Emphasis on SPG11-Related Conditions". *Nutrients* 17.21 (2025): 3344.
 16. Tang S, et al. "Ferroptosis in neurodegenerative diseases: potential mechanisms of exercise intervention". *Frontiers in Cell and Developmental Biology* 13 (2025): 1622544.
 17. Wang X, et al. "Unraveling the Vicious Cycle: Oxidative Stress and Neurotoxicity in Neurodegenerative Diseases". *FASEB BioAdvances* 7.8 (2025).
 18. Yang HM. "Mitochondrial Dysfunction in Neurodegenerative Diseases". *Cells* 14.4 (2025): 276.
 19. Zhang T, et al. "Ferroptosis in neurodegenerative diseases: mechanisms and therapeutic potential of stem cell derivatives". *Frontiers in Cell and Developmental Biology* 13 (2025).